Movement Alert｜Duality Biotherapeutics-B Rises 9.01% in Regular Trading, STAR Market IPO Status Upgraded to Inquired Amid ADC Sector Momentum

Market Focus07-06

On July 6, Duality Biotherapeutics-B rose 9.01% in regular trading, trading at HK$232.0/share, with turnover of HK$105 million. The rally was driven by the company's STAR Market IPO review status being upgraded to \"inquired,\" marking further progress in its listing process, combined with continued catalysts in the ADC sector.

According to the Shanghai Stock Exchange website, Duality Biotherapeutics' STAR Market IPO application, which was accepted on June 12, has now advanced to the inquiry stage. The company plans to raise approximately RMB 4.1 billion for new drug R&D. Meanwhile, recent industry research reports indicate the global ADC market is projected to exceed $100 billion by 2032, with Chinese companies demonstrating increasingly significant competitive advantages.

Within the Biotechnology sector, peers traded higher with REMEGEN up 3.82%, INNOVENT BIO up 3.3%, SKB BIO up 1.7%, 3SBIO up 1.69%, and AKESO up 0.59%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177976671?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177976671","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Duality Biotherapeutics-B Rises 9.01% in Regular Trading, STAR Market IPO Status Upgraded to Inquired Amid ADC Sector Momentum","media":"Market Focus","content":"<p><p>On July 6, Duality Biotherapeutics-B rose 9.01% in regular trading, trading at HK$232.0/share, with turnover of HK$105 million. The rally was driven by the company's STAR Market IPO review status being upgraded to \\\"inquired,\\\" marking further progress in its listing process, combined with continued catalysts in the ADC sector.</p><p>According to the Shanghai Stock Exchange website, Duality Biotherapeutics' STAR Market IPO application, which was accepted on June 12, has now advanced to the inquiry stage. The company plans to raise approximately RMB 4.1 billion for new drug R&D. Meanwhile, recent industry research reports indicate the global ADC market is projected to exceed $100 billion by 2032, with Chinese companies demonstrating increasingly significant competitive advantages.</p><p>Within the Biotechnology sector, peers traded higher with REMEGEN up 3.82%, INNOVENT BIO up 3.3%, SKB BIO up 1.7%, 3SBIO up 1.69%, and AKESO up 0.59%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Duality Biotherapeutics-B Rises 9.01% in Regular Trading, STAR Market IPO Status Upgraded to Inquired Amid ADC Sector Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Duality Biotherapeutics-B Rises 9.01% in Regular Trading, STAR Market IPO Status Upgraded to Inquired Amid ADC Sector Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, Duality Biotherapeutics-B rose 9.01% in regular trading, trading at HK$232.0/share, with turnover of HK$105 million. The rally was driven by the company's STAR Market IPO review status being upgraded to \\\"inquired,\\\" marking further progress in its listing process, combined with continued catalysts in the ADC sector.</p><p>According to the Shanghai Stock Exchange website, Duality Biotherapeutics' STAR Market IPO application, which was accepted on June 12, has now advanced to the inquiry stage. The company plans to raise approximately RMB 4.1 billion for new drug R&D. Meanwhile, recent industry research reports indicate the global ADC market is projected to exceed $100 billion by 2032, with Chinese companies demonstrating increasingly significant competitive advantages.</p><p>Within the Biotechnology sector, peers traded higher with REMEGEN up 3.82%, INNOVENT BIO up 3.3%, SKB BIO up 1.7%, 3SBIO up 1.69%, and AKESO up 0.59%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1177976671","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177976671","pubTimestamp":1783302687,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, Duality Biotherapeutics-B rose 9.01% in regular trading, trading at HK$232.0/share, with turnover of HK$105 million. The rally was driven by the company's STAR Market IPO review status...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动静提示|Duality Biotherapeutics-B常规交易涨9.01%，ADC板块动能下科创板IPO状态上调至问询","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 6, Duality Biotherapeutics-B rose 9.01% in regular trading, trading at HK$232.0/share, with turnover of HK$105 million. The rally was driven by the company's STAR Market IPO review status being upgraded to \\\"inquired,\\\" marking further progress in its listing process, combined with continued catalysts in the ADC sector.According to the Shanghai Stock Exchange website, Duality Biotherapeutics' STAR Market IPO application, which was accepted on June 12, has now advanced to the inquiry stage. The company plans to raise approximately RMB 4.1 billion for new drug R&D. Meanwhile, recent industry research reports indicate the global ADC market is projected to exceed $100 billion by 2032, with Chinese companies demonstrating increasingly significant competitive advantages.Within the Biotechnology sector, peers traded higher with REMEGEN up 3.82%, INNOVENT BIO up 3.3%, SKB BIO up 1.7%, 3SBIO up 1.69%, and AKESO up 0.59%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177976671","isCrawlerRequest":true}